Highly effective disease-modifying treatment as initial MS therapy
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Neurology (clinical),Neurology
Reference41 articles.
1. B cells in multiple sclerosis;Sospedra;Curr Opin Neurol,2018
2. Effect of multiple sclerosis disease-modifying therapies on B Cells and humoral immunity;Longbrake;JAMA Neurol,2016
3. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis;Baker;EBioMedicine,2017
4. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab;Baker;JAMA Neurol,2017
5. Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis;Baker;Brain,2018
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sclerosi multipla: trattamenti di base;EMC - Neurologia;2024-08
2. Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified?;Multiple Sclerosis and Related Disorders;2024-07
3. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study;Clinical Neurology and Neurosurgery;2024-05
4. Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria;Journal of Neurology;2024-03-02
5. Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina;Multiple Sclerosis and Related Disorders;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3